Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease

NCT05617508 is registered in ClinicalTrials.gov with Haukeland University Hospital as lead sponsor.

NCT NCT05617508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05617508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease
Lead sponsor
Haukeland University Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 22, 2022
Completion date
June 5, 2025
Enrollment
80 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, dementia